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The International Space Station (ISS) is falling. This is no threat to the astronauts onboard, however, because falling is part of the ISS staying 
in orbit. 
The absence of gravity beyond the Earth’s atmosphere 
is actually an illusion; at the ISS’s orbital altitude of 
approximately 250 miles above the surface, the planet’s 
gravitational pull is only 12-percent weaker than on the 
ground. Gravity is constantly pulling the ISS back to 
Earth, but the space station is also constantly traveling 
at nearly 18,000 miles per hour. This means that, even 
though the ISS is falling toward Earth, it is moving 
sideways fast enough to continually miss impacting the 
planet. The balance between the force of gravity and the 
ISS’s motion creates a stable orbit, and the fact that the 
ISS and everything in it—including the astronauts—are 
falling at an equal rate creates the condition of weightless-
ness called microgravity.
The constant falling of objects in orbit is not only an 
important principle in space, but it is also a key element 
of a revolutionary NASA technology here on Earth that 
may soon help cure medical ailments from heart disease 
to diabetes. 
In the mid-1980s, NASA researchers at Johnson Space 
Center were investigating the effects of long-term micro-
gravity on human tissues. At the time, the Agency’s shuttle 
fleet was grounded following the 1986 Space Shuttle 
Challenger disaster, and researchers had no access to the 
microgravity conditions of space. To provide a method 
for recreating such conditions on Earth, Johnson’s David 
Wolf, Tinh Trinh, and Ray Schwarz developed that same 
year a horizontal, rotating device—called a rotating wall 
bioreactor—that allowed the growth of human cells in 
simulated weightlessness. Previously, cell cultures on 
Earth could only be grown two-dimensionally in Petri 
dishes, because gravity would cause the multiplying cells 
to sink within their growth medium. These cells do not 
look or function like real human cells, which grow three-
dimensionally in the body. Experiments conducted by 
Johnson scientist Dr. Thomas Goodwin proved that the 
NASA bioreactor could successfully cultivate cells using 
simulated microgravity, resulting in three-dimensional 
tissues that more closely approximate those in the body. 
Further experiments conducted on space shuttle missions 
and by Wolf as an astronaut on the Mir space station 
demonstrated that the bioreactor’s effects were even fur-
ther expanded in space, resulting in remarkable levels of 
tissue formation.
While the bioreactor may one day culture red blood 
cells for injured astronauts or single-celled organisms 
like algae as food or oxygen producers for a Mars colony, 
the technology’s cell growth capability offers significant 
opportunities for terrestrial medical research right now. 
A small Texas company is taking advantage of the NASA 
technology to advance promising treatment applications 
for diseases both common and obscure.
partnership
In 2002, Houston-based biotechnology firm 
Regenetech Inc. (then called BioCell Innovations) 
acquired the licenses for the NASA bioreactor and a 
number of related patents for use in the burgeoning field 
of adult stem cell research. (Unlike ethically controversial 
embryonic stem cells, adult stem cells are harvested from 
sources such as blood and bone marrow.) Employing a 
novel business model that takes advantage of sponsored 
research agreements with major medical institutions like 
the University of Texas M.D. Anderson Cancer Center 
in Houston, Regenetech was able to begin testing and 
adapting the bioreactor’s capabilities for use with human 
stem cells with a first year budget of only $100,000. A 
NASA Space Act Agreement that saw the company share 
resources with Goodwin at Johnson, as well as additional 
licensing agreements between the company and the 
Cells grown in microgravity (A) tend to become more spherical than those grown on Earth (B). This demonstrates that tissues 
can grow and differentiate into distinct structures in microgravity. NASA’s rotating wall bioreactor simulates weightlessness to 
mimic this effect on Earth. 
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patent applications and has licensed out its technologies 
on a global scale. The company generates its revenue 
through research partnerships and licensing its patents to 
stem cell researchers in pursuit of treatments for every-
thing from heart disease to diabetes to liver cirrhosis. It 
is currently engaged in sponsored research agreements 
with major universities to develop stem cell therapy for 
type 1 diabetes, study blood stem cells, and create stem 
cell veterinary orthopedic treatments using the company’s 
Intrifuge cellXpansion technology.
Through an agreement with NASA, Regenetech is 
also able to offer significant help to researchers pursuing 
treatments of rare diseases that affect less than 200,000 
people in the United States and thus do not offer enough 
return on drug development investment. NASA allows 
the company to charge as little as $1,000 to $10,000 to 
license its NASA-developed technologies to researchers of 
such rare diseases.
“Our relationship with NASA has allowed us to get 
this technology out into the field for those diseases that 
otherwise might never be treated,” says Rudd. v
Intrifuge™ and cellXpansion™ are trademarks of 
Regenetech Inc.
Agency, enabled Regenetech to further complement the 
bioreactor with its own proprietary improvements. 
product outcome
Regenetech has built upon its licensed NASA technol-
ogy to create a thriving intellectual property business that 
is providing researchers with the tools to make adult stem 
cell therapy viable for the public. 
Adult stem cells are found in some types of body tissue. 
These cells are multipotent, meaning they can differenti-
ate into a specific range of specialized cells. This makes 
them appealing possibilities for treating diseases—the 
stem cells differentiate into healthy replacements for sick 
or damaged cells. Blood stem cells, for example, can trans-
form into red blood cells, white blood cells, and platelets; 
these cells could provide a potential treatment for blood 
diseases like sickle cell anemia. 
One of the richest sources of adult stem cells is bone 
marrow. 
“There are about 70 different conditions and dis-
eases where bone marrow stem cells have been used to 
regenerate tissue or treat disease,” says Donnie Rudd, 
Regenetech’s chief scientist and director of intellectual 
property. Stem cells can be harvested from a patient’s 
bone marrow through a procedure called bone marrow 
apheresis—a process that like any medical procedure 
carries some level of risk. The problem with alternative 
methods of adult stem cell harvest is getting enough 
of the cells to have therapeutic value, which is where 
Regenetech’s Intrifuge cellXpansion technology comes to 
bear. 
“We can take a sample of peripheral blood from a 
patient’s arm, separate the stem cells, put that into our 
improved NASA bioreactor, and then multiply the cells to 
a therapeutic level without all the trauma of bone marrow 
apheresis,” says Rudd.
Regenetech’s Intrifuge rotating wall bioreactor cradles 
a soup can-sized, rotating chamber that is used to expand, 
or multiply, harvested stem cells. The cell sample, con-
tained in a growth fluid, is placed in the rotating chamber 
equipped with a membrane for oxygenation and gas 
exchange. As the chamber rotates, the cells are suspended 
in a constant state of falling—similar to an object in 
space orbit. This condition is enabled by a rotating inner 
wall that reduces shear from the nutrient fluid. In this 
simulated weightlessness, the cells do not get damaged 
and die from bouncing off the sides of the chamber. They 
multiply rapidly (50–200 times in size in as few as 6 days) 
into healthy populations, providing a quicker and cheaper 
source of stem cells for therapy or medical research. 
Regenetech’s cellXpansion process is being tested for 
further enhancement by a NASA-developed electromag-
netic coil that surrounds the canister and which NASA 
developed to stimulate nerve cell growth. The coil, also 
patented by the NASA bioreactor development team and 
licensed by Regenetech, produces time varying electro-
magnetic conditions.
Regenetech started producing revenue only 5 years 
after its founding, and since acquiring the original NASA 
licenses, it has developed over 300 of its own patents and 
Regenetech scientists examine the company’s 
bioreactors. Licensed from NASA, the 
bioreactor technology allows for rapid, healthy 
cell growth, providing for a quicker, cheaper 
source of adult stem cells for therapy and 
medical research. 
